CA woman awarded $417 in Johnson & Johnson talcum powder case

Toni Houston
August 23, 2017

Earlier in May, a St. Louis, Missouri jury had awarded $110.5 million to a Virginia woman who was diagnosed with ovarian cancer in 2012.

However, Johnson & Johnson's spokesperson Carol Goodrich, in a statement, said the company will appeal against the jury's decision.

A jury ruled Monday that Johnson & Johnson (J&J) must pay a woman with ovarian cancer $417 million for failing to warn consumers of the purported dangers of the product.

But, "we will appeal [the Los Angeles] verdict because we are guided by the science, which supports the safety of Johnson's Baby Powder". As a powder, it absorbs moisture well so that is widely used in cosmetic products such as baby powder and adult facial powders for keeping skin dry and helping to prevent rashes.

The American Cancer Society notes several studies have suggested "a very slight increase" in risk of ovarian cancer for women who use talc-based powders for personal hygiene.

The woman named Eva Echeverria is an ovarian cancer patient and the verdict for her lawsuit has resulted in providing her the largest sum among all previous talcum powder lawsuit verdicts against Johnson and Johnson in the U.S. courts. Based on the studies and other allegations of later public health studies and other information, she alleged that the company was aware, or should have known, it was marketing a product harmful to women.


Echeverria had used the powder for feminine hygiene every day from the 1950s up until 2016. Mrs. Echeverria never wanted any sympathy but just wanted to spread the message to help her fellow suffers.

But, as FairWarning has reported, suspicions about talc and ovarian cancer go back decades. This marks the biggest payout Johnson & Johnson has had to shell out in a string of cases involving the same product. She only stopped after watching a news story about a woman with ovarian cancer who had also used the talc for a similar goal, she said.

Echeverria was not present, as her cancer has entered a terminal stage and she was too ill to appear.

Johnson & Johnson is preparing to defend itself and its baby powder at upcoming trials in the U.S., Goodrich said.

There has been no conclusive research on the effects of talcum powder when it comes to ovarian cancer.

The have since faced penalties of more than $300m after losing another three cases tried in the same Missouri court and are now understood to be facing thousands more pending cases across the US.

Other reports by Ligue1talk

Discuss This Article

FOLLOW OUR NEWSPAPER